mAb Development

Dec 11, 2017
By BioPharm International Editors
FDA has accepted for review Eli Lilly and Company’s biologic drug candidate that is in development for treating migraine.
Dec 08, 2017
By BioPharm International Editors
The new 30,000-L, $150-million biologics manufacturing facility in Wuxi, China, quintuples the company’s existing manufacturing capability.
Nov 29, 2017
By BioPharm International Editors
Binding Site has introduced a number of new monoclonal antibodies targeting infectious diseases, including cytomegalovirus, hepatitis (A, B, C, and D), herpes, human immunodeficiency virus (HIV), rubella, and toxoplasma.
Nov 28, 2017
By BioPharm International Editors
The acquisition gives GE Healthcare access to a nanofiber-based platform purification technology that can offer improvements in biopharmaceutical productivity.
Nov 20, 2017
By BioPharm International Editors
The agency has approved a biologic-based new molecular entity for treating hemophilia A and has expanded the indication for a leukemia drug to now treat a common form of non-Hodgkin lymphoma.
Nov 16, 2017
By BioPharm International Editors
The company’s new modules offer scalable single-pass diafiltration and were exclusively showcased during its Leadership Forum series in Westborough, MA.
Nov 16, 2017
By BioPharm International Editors
As part of the deal, J&J’s Janssen will pay an upfront payment of $50 million to research, develop, and commercialize up to six bispecific antibodies.
Nov 13, 2017
By BioPharm International Editors
The companies have established a joint laboratory to develop full continuous processing to manufacture high yields of monoclonal antibodies at reduced costs.
Oct 27, 2017
By BioPharm International Editors
AbbVie will pay a $205-million upfront payment and have the option to develop and commercialize two antibody targets globally.
Oct 27, 2017
By BioPharm International Editors
As part of the $900-million deal, Incyte will pay $150 million upfront to develop and commercialize an anti-PD-1 drug candidate from biopharmaceutical company, MacroGenics.
native1_300x100
lorem ipsum